Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Wart Type
3.2. Market Snippet by Treatment Type
3.3. Market Snippet by End-User
3.4. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising incidence of Wart
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent regulatory approvals
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Pipeline Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Wart Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type Segment
7.1.2. Market Attractiveness Index, By Wart Type Segment
7.2. Common wart (verruca vulgaris)*
7.2.1. Introduction
7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3. Flat wart, or plane wart (verruca plana)
7.4. Plantar wart, or verruca (verruca plantaris)
7.5. Genital wart (condyloma acuminatum)
7.6. Others( Periungual wart, Filiform wart, Mosaic warts)
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
8.1.2. Market Attractiveness Index, By Treatment Type Segment
8.2. Physical Destruction*
8.2.1.
8.2.1.1. Introduction
8.2.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.2.2. Cryotherapy (Freezing)
8.2.3. Surgical Removal
8.2.4. Laser Treatment
8.2.5. Others
8.3. Medication
8.3.1. Chemical Destruction
8.3.1.1. Bleomycin intralesional
8.3.1.2. Cantharidin (VP-102)
8.3.1.3. Salicylic Acid
8.3.1.4. Others
8.3.2. Immunomodulatory agent
8.3.2.1. Imiquimod 5% - topical
8.3.2.2. Interferon - intralesional
8.3.2.3. Dinitrochlorobenzene - topical
8.3.2.4. Diphencyprone topical
8.3.2.5. Retinoids - topical or oral
8.3.2.6. Others
8.3.3. Vaccines
8.3.3.1. Human papillomavirus vaccine, nonavalent (Gardasil 9)
8.3.3.2. Cervarix
8.3.4. Keratolytics
8.3.4.1. Podophyllum resin (Podocon-25, Podo-Ben-25, Podofin)
8.3.4.2. Podofilox (Condylox)
8.3.4.3. Trichloroacetic acid topical (Tri-Chlor)
8.3.4.4. 5-Fluorouracil (Efudex, Fluoroplex)
8.3.4.5. Others
8.3.5. Kunecatechins (Veregen)
8.3.6. Other
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User Segment
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3. Clinics
9.4. Others
10. By Region
10.1. Introduction
10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
10.3. Market Attractiveness Index, By Region
10.4. North America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. U.S.
10.4.6.2. Canada
10.4.6.3. Mexico
10.5. Europe
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. Germany
10.5.6.2. U.K.
10.5.6.3. France
10.5.6.4. Italy
10.5.6.5. Spain
10.5.6.6. Rest of Europe
10.6. South America
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.6.7.1. Brazil
10.6.7.2. Argentina
10.6.7.3. Rest of South America
10.7. Asia Pacific
10.7.1. Introduction
10.7.2. Key Region-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.7.6.1. China
10.7.6.2. India
10.7.6.3. Japan
10.7.6.4. Australia
10.7.6.5. Rest of Asia Pacific
10.8. Middle East and Africa
10.8.1. Introduction
10.8.2. Key Region-Specific Dynamics
10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Merck & Co., Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Dr. Scholl’s
12.3. Mylan N.V.
12.4. Novan Inc.
12.5. Pfizer, Inc.
12.6. GlaxoSmithKline plc,
12.7. Teva Pharmaceutical Industries Ltd
12.8. Verrica Pharmaceuticals
12.9. Phio Pharmaceuticals Corp.
12.10. AIM ImmunoTech, Inc. (List Not Exhaustive)
13. DataM Intelligence
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us